| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| General and administrative | 2,410,516 | |||
| Research and development | 24,407 | |||
| Goodwill impairment | 0 | |||
| Long-lived asset impairment | 831,915 | |||
| Depreciation and amortization | 41,522 | |||
| Total operating expenses | 3,308,360 | |||
| Loss from operations | -3,308,360 | |||
| Change in fair value of contingent consideration | 370,000 | |||
| Change in fair value of equity securities | 156,849 | |||
| Gain on bankruptcy of subsidiary | 12,019,227 | |||
| Loss on extinguishment of debt | -6,329,592 | |||
| Interest expense | 122,400 | |||
| Interest income and other income (expense) | 33,297 | |||
| Total other income (expense) | 6,127,381 | |||
| Net income (loss) | 2,819,021 | |||
| Basic net loss per common share | 0.13 | |||
| Diluted net loss per common share | 0.13 | |||
| Weighted average number of shares of common stock outstanding - basic | 22,520,245 | |||
| Weighted average number of shares of common stock outstanding - diluted | 22,520,245 | |||
Lunai Bioworks Inc. (LNAI)
Lunai Bioworks Inc. (LNAI)